Regenxbio Inc
NASDAQ:RGNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Regenxbio Inc
NASDAQ:RGNX
|
US |
|
Lake Winn Resources Corp
XTSX:LWR
|
CA |
|
S
|
Sandfire Resources Ltd
OTC:SFRRF
|
AU |
Intrinsic Value
The intrinsic value of Regenxbio Inc (RGNX) under the Base Case is 10.97 USD per share.
Compared with the current market price of 7.06 USD, the stock appears
Undervalued by 36% .
The intrinsic value is calculated using the DCF method. Operating margin recovers from -95% last year to 25% by 2031. Revenue grows about 21% a year over the next five years, about 11 times its five-year pace of 2%. The forecast years subtract value, so the estimate rests entirely on the years after 2031.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Regenxbio Does
Regenxbio is a biotechnology company that develops gene therapy medicines. It works by designing viral vectors that can deliver working genes into a patient’s cells, mainly for rare and serious diseases. The company’s business is built around research, clinical development, and licensing its gene therapy technology to drug makers that want to use it in their own programs.
- Headquarters
- United States of America US
- Employees
- 371
- IPO date
- Sep 17, 2015
Revenue & Expenses Breakdown
Regenxbio Inc
Earnings Waterfall
Regenxbio Inc
The intrinsic value for Regenxbio Inc (RGNX) under the Base Case is 10.97 USD.
Compared with the current market price of 7.06 USD, the stock appears Undervalued by 36% .